DEVELOPING UNIQUE Allosteric modulators of integrins for Triple Negative Breast Cancer

AVIPERO has unique Platform technology with multiple applications/indications.

AVIPERO is a strong team with track record in drug development in cancer. At Avipero we aspire to revolutionize the treatment of malignant and degenerative diseases worldwide. We are dedicated to the study of breast cancer, our pharmaceutical research company prioritizes the development of a non-destructive cure for this metastatic disease.

Learn more about our science

Our Revolutionary Approach to Cell Restoration

Our targeted therapeutic pharmacology refines integrins and tissues instead of killing them. This transformative nature of our platform comes from our unique understanding of changes in cell behavior in different illnesses.

This approach retains rogue cells, which cause malignant tumors. Instead of shutting them down, it brings them back to their original state, therefore, modifying disease progression and reducing severe side effects. This form of treatment has been proven effective on metastatic cancers as well as various degenerative diseases and viral infections.

Learn More About Our Research

For more information about AVIPERO Ltd. and our research, please feel free to contact us anytime. We’d be more than happy to answer any questions you may have.

Connect With Us